Kyverna Therapeutics (NASDAQ: KYTX) has announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS) in the Journal of the American Medical Association (JAMA).
According to Kyverna, these published data were presented in a late-breaking oral presentation at the American Academy of Neurology (AAN) Annual Meeting in April 2026. Kyverna also recently shared its one-year durability data from the KYSA-8 trial at MS Toronto, the joint ACTRIMS-ECTRIMS meeting.
In a statement, Marinos C. Dalakas, MD, PhD, professor of neurology, Thomas Jefferson University, senior author and lead study investigator of the clinical trial, commented, “The publication of the KYSA-8 registrational data in JAMA Neurology underscores the unique potential of miv-cel to liberate patients with stiff person syndrome from life-long disease burden and chronic immunotherapy use. Importantly, for patients and the field, miv-cel showed a well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS. Having cared for patients with SPS for more than 30 years and witnessed the debilitating impact of this progressive disease, I believe miv-cel can change the therapeutic landscape for SPS by offering the potential to reverse patient disability. It’s truly remarkable to see some of my patients who, for years, required assistive devices to now walking independently, in some cases even running.”
